Journal of Hematology and Blood Disorders

Dr. Yun Dai is Associate Professor of Medicine in the Division of Hematology/Oncology. He received post-doc training in Molecular Biology and Biochemistry at the University of Pennsylvania, and in Hematology/Oncology and Clinical and Translational Research at the Virginia Commonwealth University. Dr. Dai’s research has been supported by RO1, R21, Multiple Myeloma SPORE, and Lymphoma SPORE grants from NCI/NIH, and awards from research foundations/societies, including Multiple Myeloma Research Foundation, Leukemia and Lymphoma Society, and V Foundation. His research has resulted in 6 multi-institutional and NCI-supported phase I or II clinical trials in treatment of patients with leukemia, lymphoma, myeloma, and other heme malignancies, parts of which have been presented at the ASCO and ASH annual meetings.

Dr. Dai has served on review panels of the NIH/NCI and the Israeli-French High Council for Scientific & Technological Research, as well as the Editorial Board Member for many journals. He has extensively served as a peer reviewer for numerous research journals. He has been an active member of AACR and ASH in good-standing since 2002 and 2005, respectively. Dr. Dai received his M.D. and PhD degrees from Southern Medical University (SMU, Guangzhou, Guangdong, China), where he received training in Medicine, Histology/Cell Biology and Embryology/Development Biology. He has published 65 original research papers and 9 reviews/commentaries in peer-review journals, as well as 6 invited book chapters. His work has been presented in international conferences, including oral presentations at the AACR and ASH annual meetings.

Dr. Dai’s primary research interest is in

The translational and pre-clinical research of novel targeted cancer therapy, primarily focusing on hematological malignancies.